Systemic Symptoms Unlikely to Occur from Contaminated Moderna Jabs: Japan Vaccinology Society
To read the full story
Related Article
- No Major Safety Concerns for COVID-19 Jabs: MHLW Panels
January 24, 2022
- Second Case of TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
December 27, 2021
- Japan Panels Agree to Add Myocarditis as ADRs for Pfizer, Moderna Vaccines
December 6, 2021
- TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
November 15, 2021
- MHLW Panels Continue to See No Major Safety Concerns for COVID-19 Jabs
October 25, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW Panels
October 4, 2021
- “Human Error” Is to Blame for Contamination of Moderna COVID-19 Vaccines: Report
October 4, 2021
- Tainted Moderna Jabs Run Afoul of PMD Law: Minister
September 16, 2021
- Causal Link between Deaths and Recalled Batch of Moderna Jab “Indeterminable”
September 13, 2021
- Post-Vaccination Death Cases Being Investigated with Integrity: Takeda
September 8, 2021
- Takeda Recalling Suspended Batches of Moderna Jabs in Japan; Administrative Action Possible
September 2, 2021
ACADEMIA
- Medical Society Says “No” to Discontinuation of Theodur Despite Supply Struggle
February 5, 2025
- Refusal to See Patients due to Kostaive Shots Might Violate “Duty of Care”: Lawyer
December 17, 2024
- Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
December 6, 2024
- Consortium on Pediatric Drug Development Up and Running from This Fiscal Year
November 25, 2024
- Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan
November 8, 2024
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…